Gabapentin treatment for muscle cramps: An open-label trial

Mariano Serrao, Paolo Rossi, Patrizio Cardinali, Gabriele Valente, Leoluca Parisi, Francesco Pierelli

Research output: Contribution to journalArticle

Abstract

To evaluate the efficacy and safety of gabapentin in the treatment of muscle cramps, we engaged an open-label trial with a group of 30 patients with frequent (>5 cramps/week), stable, long-lasting cramps, associated with different diseases. Gabapentin was effective in reducing the frequency and severity of muscle cramps and associated sleep disturbances (clinical outcome measures) within the first 2 weeks of medication at 600 mg/d. At the 1 month control (mean dosage, 825 ± 35 mg), almost every patient had responded to treatment and two thirds experienced a total remission of symptoms. After 3 months of therapy (mean dosage, 892 ± 180 mg), cramps disappeared in 100% of patients and this benefit persisted as long as 6 months. Additionally, we evaluated in 10 patients the Cramps Threshold Frequency (CTF) (neurophysiological outcome measure) before and during gabapentin treatment. Gabapentin significantly increased the CTF, returning it to normal values. With the limitation of an open-label methodology, our clinical and neurophysiologic experience suggests that a gabapentin dose of 600-1200 mg/d would be helpful in the treatment of muscular cramps.

Original languageEnglish
Pages (from-to)45-49
Number of pages5
JournalClinical Neuropharmacology
Volume23
Issue number1
DOIs
Publication statusPublished - Jan 2000

Fingerprint

Muscle Cramp
Therapeutics
Outcome Assessment (Health Care)
gabapentin
Sleep
Reference Values
Safety

Keywords

  • Drug therapy
  • Gabapentin
  • Muscle cramps

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Clinical Neurology
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Gabapentin treatment for muscle cramps : An open-label trial. / Serrao, Mariano; Rossi, Paolo; Cardinali, Patrizio; Valente, Gabriele; Parisi, Leoluca; Pierelli, Francesco.

In: Clinical Neuropharmacology, Vol. 23, No. 1, 01.2000, p. 45-49.

Research output: Contribution to journalArticle

Serrao, Mariano ; Rossi, Paolo ; Cardinali, Patrizio ; Valente, Gabriele ; Parisi, Leoluca ; Pierelli, Francesco. / Gabapentin treatment for muscle cramps : An open-label trial. In: Clinical Neuropharmacology. 2000 ; Vol. 23, No. 1. pp. 45-49.
@article{a3def2bac5e04e0484ce7dc8b94fd4ff,
title = "Gabapentin treatment for muscle cramps: An open-label trial",
abstract = "To evaluate the efficacy and safety of gabapentin in the treatment of muscle cramps, we engaged an open-label trial with a group of 30 patients with frequent (>5 cramps/week), stable, long-lasting cramps, associated with different diseases. Gabapentin was effective in reducing the frequency and severity of muscle cramps and associated sleep disturbances (clinical outcome measures) within the first 2 weeks of medication at 600 mg/d. At the 1 month control (mean dosage, 825 ± 35 mg), almost every patient had responded to treatment and two thirds experienced a total remission of symptoms. After 3 months of therapy (mean dosage, 892 ± 180 mg), cramps disappeared in 100{\%} of patients and this benefit persisted as long as 6 months. Additionally, we evaluated in 10 patients the Cramps Threshold Frequency (CTF) (neurophysiological outcome measure) before and during gabapentin treatment. Gabapentin significantly increased the CTF, returning it to normal values. With the limitation of an open-label methodology, our clinical and neurophysiologic experience suggests that a gabapentin dose of 600-1200 mg/d would be helpful in the treatment of muscular cramps.",
keywords = "Drug therapy, Gabapentin, Muscle cramps",
author = "Mariano Serrao and Paolo Rossi and Patrizio Cardinali and Gabriele Valente and Leoluca Parisi and Francesco Pierelli",
year = "2000",
month = "1",
doi = "10.1097/00002826-200001000-00008",
language = "English",
volume = "23",
pages = "45--49",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Gabapentin treatment for muscle cramps

T2 - An open-label trial

AU - Serrao, Mariano

AU - Rossi, Paolo

AU - Cardinali, Patrizio

AU - Valente, Gabriele

AU - Parisi, Leoluca

AU - Pierelli, Francesco

PY - 2000/1

Y1 - 2000/1

N2 - To evaluate the efficacy and safety of gabapentin in the treatment of muscle cramps, we engaged an open-label trial with a group of 30 patients with frequent (>5 cramps/week), stable, long-lasting cramps, associated with different diseases. Gabapentin was effective in reducing the frequency and severity of muscle cramps and associated sleep disturbances (clinical outcome measures) within the first 2 weeks of medication at 600 mg/d. At the 1 month control (mean dosage, 825 ± 35 mg), almost every patient had responded to treatment and two thirds experienced a total remission of symptoms. After 3 months of therapy (mean dosage, 892 ± 180 mg), cramps disappeared in 100% of patients and this benefit persisted as long as 6 months. Additionally, we evaluated in 10 patients the Cramps Threshold Frequency (CTF) (neurophysiological outcome measure) before and during gabapentin treatment. Gabapentin significantly increased the CTF, returning it to normal values. With the limitation of an open-label methodology, our clinical and neurophysiologic experience suggests that a gabapentin dose of 600-1200 mg/d would be helpful in the treatment of muscular cramps.

AB - To evaluate the efficacy and safety of gabapentin in the treatment of muscle cramps, we engaged an open-label trial with a group of 30 patients with frequent (>5 cramps/week), stable, long-lasting cramps, associated with different diseases. Gabapentin was effective in reducing the frequency and severity of muscle cramps and associated sleep disturbances (clinical outcome measures) within the first 2 weeks of medication at 600 mg/d. At the 1 month control (mean dosage, 825 ± 35 mg), almost every patient had responded to treatment and two thirds experienced a total remission of symptoms. After 3 months of therapy (mean dosage, 892 ± 180 mg), cramps disappeared in 100% of patients and this benefit persisted as long as 6 months. Additionally, we evaluated in 10 patients the Cramps Threshold Frequency (CTF) (neurophysiological outcome measure) before and during gabapentin treatment. Gabapentin significantly increased the CTF, returning it to normal values. With the limitation of an open-label methodology, our clinical and neurophysiologic experience suggests that a gabapentin dose of 600-1200 mg/d would be helpful in the treatment of muscular cramps.

KW - Drug therapy

KW - Gabapentin

KW - Muscle cramps

UR - http://www.scopus.com/inward/record.url?scp=0033960908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033960908&partnerID=8YFLogxK

U2 - 10.1097/00002826-200001000-00008

DO - 10.1097/00002826-200001000-00008

M3 - Article

C2 - 10682230

AN - SCOPUS:0033960908

VL - 23

SP - 45

EP - 49

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - 1

ER -